Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog

Xenobiotica

Volumn 28, Issue 8, 1998, Pages 759-766

  Mae, T ^a   Hosoe, K ^a   Yamamoto, T ^a   Hidaka, T ^a   Ohashi, T ^a   Kleeman, J M ^b   Adams, P E ^b  

^a KANEKA CORPORATION   (Japan)

^b 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; MICROSOME ENZYME; RIFALAZIL; RIFAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; LIVER METABOLISM; LIVER MICROSOME; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; XENOBIOTIC METABOLISM;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031691174     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239173     Document Type: Article

References (34)

1. BARRY, M. and FEELY, J., 1990, Enzyme induction and inhibition. Pharmacology and Therapeutics, 48, 71-94.
2. BERMUDEZ, L. E., KOLONOSKI, P., YOUNG, L. S. and INDERLIED, C. B., 1994, Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrobial Agents and Chemotherapy, 38, 1844-1848.
3. DURAND, D. V., HAMPDEN, C., BOOBIS, A. R., PARK, B. K. and DABIES, D. S., 1986, Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. British Journal of Clinical Pharmacology, 21, 1-7.
4. EGUCHI, K., NISHIBE, Y., BABA, T. and OHNO, K., 1996, Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C11 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica, 26, 755-764.
5. EMORI, M., SAITO, H., SATO, K., TOMIOKA, H., SETOGAWA, T. and HIDAKA, T., 1993, Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrobial Agents and Chemotherapy, 37, 722-728.
6. GIBSON, G. G. and SKETT, P., 1994, In vitro assays for drug-metabolizing enzymes. In Introduction to Drug Metabolism, 2nd edn (Glasgow: Blackie Academic & Professional), pp. 217-240.
7. GRANGE, J. M., WINSTANLEY, P. A. and DAVIES, P. D. O., 1994, Clinically significant drug interactions with antituberculosis agents. Drug Safety, 11, 242-251.
8. HOSOE, K., MAE, T., KONISHI, E., FUJII, K., YAMASHITA , K., YAMANE, T., HIDAKA, T. and OHASHI, T., 1996, Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrobial Agents and Chemotherapy, 40, 2749-2755.
9. IMAI, Y., ITO, A. and SATO, R., 1966, Evidence for biochemically different types of vehicles in the hepatic microsomal fraction. Journal of Biochemistry, 60, 417-428.
10. INDERLIED, C. B., BARBARA-BURNHAM, L., WU, M., YOUNG, L. and BERMUDEZ, L. E., 1994, Activity of the benzoxazinorifamycin KRM-1648 against the Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy, 38, 1838-1843.
11. KLEMENS, S. P., GROSSI, M. A. and CYNAMON, M. H., 1994, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy, 38, 2245-2248.
12. KUZE, F., YAMAMOTO, T., AMITANI, R. and SUZUKI, K., 1991, In vitro activities of new rifamycin derivatives against mycobacteria. Kekkaku, 66, 7-12.
13. LIU, D. Y. and WANG, Y. S., 1990, Inductive effects of rifapentine on mice hepatic mixed function oxidase system. Methods and Findings in Experimental and Clinical Pharmacology, 12, 109-113.
14. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
15. LUNA-HERRERA, J., REDDY, M. V. and GANGADHAHAM, P. R. J., 1995, In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy, 39, 440-444.
16. MAE, T., HOSOE, K., FUJII, K., YAMASHITA, K., YAMANE, T., HIDAKA, T. and OHASHI, T., 1996, In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica, 26, 793-802.
17. MATSUBARA, T., KOIKE, M., TOUCHI, A., TOCHINO, Y. and SUGENO, K., 1976, Quantitative determination of cytochrome P-450 in rat liver homogenate. Analytical Biochemistry, 75, 596-603.
18. NASH, T., 1953, The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochemistry, 55, 416-421.
19. OESCH, F., ARAND, M., STROLIN BENEDETTI, CASTELLE, M.G. and DOSTERT, P., 1996, Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. Journal of Antimicrobial Chemotherapy, 37, 1111-1119.
20. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2379-2385.
21. PERUCCA, E., GRIMALDI, R., FRIGO, G. M., SARDI, A., MOING, H. and OHNHAUS, E. E., 1988, Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. European Journal of Clinical Pharmacology, 34, 595-599.
22. SAITO, H., TOMIOKA, H., SATO, K., EMORI, M., YAMANE, T., YAMASHITA, K., HOSOE, K. and HIDAKA, T., 1991, In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy, 35, 542-547.
23. 5, NADPH-P450 reductase and lipid on the rate of 6β-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein. Archives of Biochemistry and Biophysics, 318, 314-321.
24. SKINNER, M. H. and BLASCHKE, T. E., 1995, Clinical pharmacokinetics of rifabutin. Clinical Pharmacokinetics, 28, 115-125.
25. STROLIN BENEDETTI, M. and DOSTERT, P., 1994, Induction and autoinduction properties of rifamycin derivatives : a review of animal and human studies. Environmental Health Perspectives, 102(suppl. 9), 101-105.
26. STROLIN BENEDETTI, M., EFTHYMIOPOULOS, C., SASSELLA, D., MORO, E. and REPETTO, M., 1990, Autoinduction of rifabutin metabolism in man. Xenobiotica, 20, 1113-1119.
27. TOMIOKA, H., SAITO, H., FUJII, K., SATO, K and HIDAKA, T., 1993, In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by the radiometric method. Antimicrobial Agents and Chemotherapy, 37, 67-70.
28. TOMIOKA, H., SAITO, H., SATO, K., YAMANE, T., YAMASHITA, K., HOSOE, K., FUJII, K. and HIDAKA, T., 1992, Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy, 36, 387-393.
29. VENKATESAN, K., 1992, Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics, 22, 47-65.
30. WALLACE, R. J. JR, BROWN, B. A., GRIFFITH, D. E., GIRARD, W. and TANAKA, K., 1995, Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. Journal of Infectious Diseases, 171, 747-750.
31. WASKELL, L. A., VIGNE, J. L. and VERGERES, G., 1991, Site of action of substrates requiring cytochrome b5 for oxidation by cytochrome P450. Methods in Enzymology, 206, 523-529.
32. YAMAMOTO, T., AMITANI, R., KUZE, F. and SUZUKI, K., 1990, In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex. Kekkaku, 65, 805-810.
33. YAMANE, T., HASHIZUME, T., YAMASHITA, K., KONISHI, E., HOSOE, K., HIDAKA, T., WATANABE, K., KAWAHARADA, H., YAMAMOTO, T. and KUZE, F., 1993, Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxaziorifamycin derivatives. Chemical and Pharmaceutical Bulletin, 41, 148-155.
34. ZHANG, X. J. and THOMAS, P. E., 1996, Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metabolism and Disposition, 24, 23-27.